Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ancient remedy meets modern science: can herbs and acupressure tame asthma and hay fever?

NCT ID NCT07540351

Disease control Sponsor: Beijing Daxing District Hospital of Integrated Chinese and Western Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a traditional Chinese medicine approach—Yiqi Wenyang Sanhan Formula taken orally plus acupoint application—for people with both allergic rhinitis (hay fever) and asthma during a quiet phase. The goal is to see if it can improve disease control and prevent flare-ups. 188 participants aged 16-79 will be randomly assigned to treatment or placebo in a double-blind design.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Yiqi Wenyang Sanhan Formula (Chinese herbal medicine) combined with acupoint application
What this could lead to
If successful, this could provide a new option to prevent flare-ups and improve quality of life for people with both allergic rhinitis and asthma.
What could go wrong
This is an early phase 1 trial, so safety and effectiveness are not yet proven. The herbal formula may not work better than placebo, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 188 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 to 79 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Fulfilled the western medicine diagnostic criteria for CARAS. 2. Had clearly defined seasonal attack characteristics and were diagnosed with CARAS of the yang-deficiency syndrome type during the remission stage. 3. Were aged 16-79 years. 4. Were informed of the study details and provided written informed consent. 5. Had a general physical condition and mental status sufficient to ensure the objective and accurate reporting of symptom characteristics and treatment responses. Exclusion Criteria: 1. A diagnosis of vasomotor rhinitis or non-allergic rhinitis with eosinophilia syndrome. 2. Known or suspected allergy to any component of the study medication, or any contraindication to the study medication or glucocorticoid therapy. 3. Current participation in another drug trial, or concomitant use of other oral traditional Chinese medicines or external medicinal patches. 4. The presence of severe primary diseases affecting major organs or systems, including the cardiovascular, hepatic, renal, or hematopoietic systems, or the presence of a psychiatric disorder. 5. Pregnancy or lactation. 6. Inability to clearly provide syndrome-related information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic rhinitis with asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Rhinitis, Allergic

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Allergic rhinitis with asthma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.